GOC’s 19th Annual CPD Meeting
It is with great pleasure that we invite you on behalf of the Executive of The Society of Gynecologic Oncology of Canada and the CPD Program Planning Committee to attend the 19th Annual Continuing Professional Development meeting in Toronto, Ontario May 2-3, 2019 at the Sheraton Toronto Centre Hotel.
Not to miss on Thursday May 2nd: GOC's Course on Molecular Biology for Gynecologic Cancers
On Thursday May 2nd, The Society of Gynecologic Oncology of Canada presents the Molecular Biology for Gynecologic Cancers: Hot Topics in Molecular Oncology.
This course will discuss current and relevant molecular and cell biology discoveries and highlight how these insights impact our understanding of the pathogenesis and treatment of cancer. The course is geared to clinicians with a view to broaden their knowledge of the basic science of cancer and the development of novel therapies for cancer.
Faculty includes several renowned scientists as well as none other than the founder of the HPV test Dr. Attila Lorincz.
Register for the course while registering for our 19th Annual CPD Meeting.
Please navigate this conference site for full details.
We look forward to seeing you in Toronto!
May 2, 2019 - May 3, 2019
Sheraton Toronto Centre Hotel
123 Queen Street, W., Toronto, Ontario
GOC’s 19th Annual Continuing Professional Development Meeting
- To improve our understanding of the role of robotics-assisted surgery for gynecologic cancers;
- To review the indications for PARP inhibitor use in gynecologic oncology;
- To describe an interdisciplinary approach to malignant bowel obstruction;
- To understand the landscape of immunotherapy clinical trials in gynecologic oncology in Canada and how to develop an immune-oncology program in the hospital;
- To discuss the role of minimally invasive surgery and its limitations in the treatment of cervix cancer;
- To summarize the advances in radiotherapy in the treatment of cervix cancer and vulvar cancer;
- To summarize the role of hormone replacement therapy for gynecologic oncology patients;
- To discuss the applications of radiotherapy in palliative circumstances;
- To introduce the principles of pelvic physiotherapy and how it can be helpful for gynecologic oncology patients;
- To review new perspectives in HPV testing;
- To discuss the new advances in pathology and translational research for vulvar cancer and the resulting upcoming systemic therapies;
- To review considerations for the integration of oncology biosimilars in clinical practice.
MAY 2, 2019
SHERATON TORONTO CENTRE HOTEL
PRIVATE COMMITTEE MEETINGS/EVENTS (ATTENDANCE REQUESTED BY SEPARATE INVITATIONS) Time Committee/Event Meeting Room 8:00-9:00 Fellow exams: examiner breakfast & orientation Churchill Room 9:15-13:00 Fellow exams: examinations Parlors 11:45-12:45 CG2 meeting Pinnacle Room 13:00-15:15 Board of Directors meeting Pinnacle Room 15:30-17:15 Course on Molecular biology for gynecologic cancers: hot topics in molecular oncology City Hall 17:15-18:15 Reception for fellows-in-training and biology course participants City Hall Foyer 18:30-21:00 GOC Nursing Group meeting Pinnacle Room THURSDAY, MAY 2, 2019
MEETING ROOM: CITY HALL
GOC COURSE ON MOLECULAR BIOLOGY FOR GYNECOLOGIC CANCERS: HOT TOPICS IN MOLECULAR ONCOLOGY
1. Discuss how advancements in basic science lead to specific improvements in cancer care for women.
2. Review the description, classification, biology and significance of the chromosomal changes found
3. Discuss the current approaches and pitfalls to measuring ctDNA and how measuring ctDNA will improve the treatment of cancer and specifically GYN Cancers.
4. Discuss molecular biology of HPV infection including typing, oncogenicity, and detection.
Time Presentation Speaker 15:30-17:15 The GOC molecular biology of cancer course – introduction Mark Carey, MD Chromosome instability: early insight into high grade serous ovarian cancer
1) Distinguish between the different types of genome instability. (Medical Expert/Scholar)
2) Define, classify and measure the important characteristic of the chromosomal changes found in cancer and show an example in high grade serous ovarian cancer. (Medical Expert/Scholar)
3) Identify important characteristics of chromosomal instability in cancer and how they can be exploited for therapeutic advantage. (Medical Expert/Scholar)
Mark Nachtigal, PhD Circulating tumour DNA: how will it improve gynecologic cancer diagnosis and management?
1) Describe how circulating tumour DNA (ctDNA) was discovered and measured. (Medical Expert/Scholar)
2) Discuss the current approaches and pitfalls to measuring ctDNA. (Medical Expert/Scholar)
3) Review examples of how measuring ctDNA will improve the treatment of cancer and specifically GYN Cancers.(Medical Expert/Scholar)
Scott Bratman, MD, PhD Molecular testing for HPV and cervix cancer
1) Discuss a brief history and discovery of HPV as an oncogenic virus. (Medical Expert/Scholar)
2) Review the molecular determinants of the different HPV types and the biology of their oncogenicity. (Medical Expert/Scholar)
3) Describe the methods for identifying and measuring HPV infection in humans.(Medical Expert/Scholar)
4) Discuss new developments in molecular diagnosis of cervical cancer including novel epigenetic biomarkers.(Medical Expert/Scholar)
Attila Lorincz, PhD Wrap-up discussion FRIDAY, MAY 3, 2019
MEETING ROOM: CIVIC BALLROOM
8:00 Welcome and announcements
Get your EventMobi going!
Jim Bentley, MD (GOC President)
Susie Lau, MD (CPD Committee Chair)
8:10 Incorporation of robotics in gyn oncology: societal and cost perspectives
1) To appraise the role of incorporating robotic platform for surgery in Gynecologic Oncology. (Medical Expert/Scholar)
2) To appraise the currently published experiences regarding the societal and cost impacts with the incorporation of robotic surgical platforms. (Medical Expert/Scholar)
3) To support the appropriate use and acquisition of robotic surgical platforms. (Scholar/Health Advocate)
Mario Leitao, MD, FACOG, FACS 8:35 PARP inhibitors – past, present, future: how they fit in our armamentarium
1) Identify the principle studies in ovarian cancer that lead to current recommendations of Parp inhibitor use in the recurrent and maintenance settings.
2) Understand the direction of current and future research for Parp inhibitors in the management of ovarian cancer.
Stephanie Lheureux, MD 9:00 An innovative interdisciplinary proactive approach to ambulatory management of malignant bowel obstruction in gynecology oncology
1) To propose a new interdisciplinary ambulatory care model for gynecology oncology patients with or at risk of malignant bowel obstruction. (Medical Expert/Scholar)
2) To discuss the impact of a proactive oncology nurse-led ambulatory symptom management algorithm for gynecology oncology patients with or at risk of developing malignant bowel obstruction. (Medical Expert/Scholar)
3) To build capacity through shared knowledge with other cancer centres to improve quality of life for gynecology oncology patients with or at risk of malignant bowel obstruction. (Medical Expert/Collaborator)
Nazlin Jivraj, RN, BScN, CON(C) 9:25 Ovarian Cancer Canada: The World Ovarian Cancer Coalition Every Women Study
1) Participants will be able to describe the mandate of the World Ovarian Cancer Coalition.
2) Participants will be able to describe the scope of the Every Woman Study.
3) Participants will be able to interpret the key findings identified in the Study.
Amit Oza, MD
9:40 BREAK 10:10 Biosimilars – the new kid on the block: considerations for the integration of oncology biosimilars in clinical practice
1) Distinguish the regulatory pathway for reference biologics from biosimilars. (Medical Expert/Scholar)
2) Evaluate the efficacy of biosimilars, approved by Health Canada, the EMA & FDA, vs reference biologic drugs for oncology indications. (Medical Expert/Scholar)
3) Apply relevant criteria for adopting biosimilars into oncology practice. (Medical Expert/Scholar)
Victoria Mandilaras, MD 10:45 Minimally invasive surgery and radical hysterectomy for cervical cancer
1) Discuss the strengths and limitations of the recently published randomized trial assessing minimally invasive surgery for cervical cancer. (Medical Expert/Scholar)
2) Better assess the role of minimally invasive surgery for cervical cancer. (Medical Expert/Scholar)
3) Appraise their own outcomes after surgery for radical hysterectomy and support their approach or need for change in approach. (Medical Expert/Health Advocate)
Mario Leitao, MD, FACOG, FACS 11:30 Updates in the management of cervical cancer
1) To discuss the role of MR imaging in the management of locally advanced cervical cancer. (Medical Expert/Scholar)
2) To review the evidence supporting the use of MR-based brachytherapy for cervical cancer. (Medical Expert/Scholar)
3) To review new advances and innovations in cervical cancer management. (Medical Expert/Scholar)
Akila Viswanathan, MD 11:55 Announcements Susie Lau, MD 12:00 LUNCH 13:15 New perspectives in HPV testing
1) Updated concepts on HPV infection and human disease and reasons for an indefinite ongoing need for HPV screening.
2) The role of self-sampling for HPV and use of the test for underdeveloped regions.
3) The role of cytology and HPV16/18 genotyping as triage tests for high-risk HPV positive women.
4) The potential added value of a new epigenetics molecular classifier to determine oncogenicity of HPV and risk of cervical cancer in screened women.
Attila Lorincz, MD 13:40 Pathology/translational research for vulvar cancer: updates in nomenclature and new insights in molecular pathogenesis
1) Summarize the complex and evolving nomenclature used to describe squamous precursor (pre-neoplastic) lesions in the vulva. (Medical Expert/Scholar)
2) Discuss the challenges in diagnosing vulvar squamous precursor on small biopsies using histology alone and reasons for frequent clinico-pathologic discrepancies. (Medical Expert/Scholar)
3) Describe the molecular pathogenesis of vulvar squamous cell carcinomas and its clinical relevance. (Medical Expert/Scholar)
Lien Hoang, MD 14:05 Advances in radiation therapy in vulvar cancer
1) Describe prognostic factors for vulvar cancer. (Medical Expert/Scholar)
2) Review vulvar contouring atlas for IMRT. (Medical Expert/Scholar)
3) Discuss the use of chemoradiation and radiation dose escalation for locally advanced vulvar cancer. (Medical Expert/Scholar)
Akila Viswanathan, MD 14:30 BREAK 15:00 Treatment induced menopause in the gynecology oncology patient: the role of hormone therapy
1) Illustrate the implications of an early diagnosis of menopause for the cancer patient. (Medical Expert/Scholar)
2) Discuss the role of menopausal hormone therapy in this patient population. (Medical Expert/Scholar)
3) Describe the potential risks of menopausal hormone therapy. (Medical Expert/Scholar)
4) Define an approach to prescribing hormone replacement to these patients. (Medical Expert/Scholar)
Debra Evaniuk, MD 15:25 Radiation therapy in ovarian cancer: have we come full circle or is it just “spot welding”
1) Describe the role radiation has played in ovarian cancer. (Medical Expert/Scholar)
2) Define: WART, IMRT and SBRT. (Medical Expert/Scholar)
3) Discuss the role of SBRT in the current paradigm of ovarian cancer management. (Medical Expert/Scholar)
4) Identify future opportunities to combine radiation and systemic treatments. (Scholar/Collaborator)
Aman Taggar, MD 15:50 Managing pelvic floor dysfunction in the oncology patient.
1) Describe the role of physiotherapy in the oncology gynecology patient. (Medical Expert/Scholar)
2) Describe and identify common pelvic floor dysfunctions in the oncology patient. (Medical Expert/Scholar)
3) Identify the appropriateness for oncology patient referrals to pelvic floor rehabilitation. (Medical Expert/Scholar)
Amanda Matos 16:15 Update on clinical trials of immune checkpoint inhibitors in gynecologic cancer
1) To define the approved indications for immune checkpoint inhibitors across all cancers in the USA and Canada (Scholar).
2) To summarize the current and pending immunotherapy clinical trials in ovarian, endometrial and cervical cancers (Medical Expert/ Scholar)
3) To discuss opportunities for future collaboration as a Canadian collective in gynecologic cancer (Collaborator).
Stephen Welch, MD 16:30 Preparing for success in immuno-oncology therapy
1) Explain the basic interplay between cancer and the immune system. (Medical Expert/Scholar)
2) Identify the common and uncommon toxicities of immunotherapy. (Medical Expert/Scholar)
3) Apply knowledge of toxicity to cases. (Medical Expert/Scholar)
4) Organize multi-disciplinary input into monitoring and treating IO toxicities. (Communicator/Collaborator/Health Advocate/Professional)
Rosalyn Juergens, MD 17:00 Adjournment FRIDAY, MAY 3, 2019
MEETING ROOM: SIMCOE
17:00-18:00 Fellow oral examination review for the candidates ONLY Danielle Vicus, MD FRIDAY, MAY 3, 2019
SOCIAL EVENT AND LEADERSHIP LECTURE AT ARCADIAN LOFT
18:00-22:00 GOC’s 18th Annual Leadership Speaker Dinner at Arcadian Loft
With Guest Speaker Dr. Attila Lorincz
SATURDAY, MAY 4, 2019 8:00-15:30 CCTG Gyne Disease Site Committee meeting Eaton Chelsea Hotel
Registration Category Early bird
reg fee until
Reg fee as of
GOC member physicians $275.00 $365.00 $400.00 GOC member fellows, physician assistants $150.00 $225.00 $275.00 GOC member nurses, residents, researchers, pharmacists $125.00 $200.00 $250.00 Non-member physicians $475.00 $565.00 $600.00 Non-member fellows, physician assistants $225.00 $300.00 $350.00 Non-member nurses, residents, researchers, pharmacists $200.00 $275.00 $325.00 Retired GOC Members $ 80.00 $155.00 $200.00
Am I registered?
How do I register?
Register on-line – scroll down page.
Early bird registration available until March 18th!
Cancellation and Refund policy: Fees to attend the CPD conference will be refunded if a written notice of cancellation is received no later than April 9, 2019. An administration fee of $50 will apply. Refunds will not be granted after this date.
The cost of dinner will be refunded if a written notice of cancellation is received no later than April 19, 2019. An administration fee of $25 will apply. Refunds will not be granted after this date.
Bookings are closed for this event.
Accomodations & Travel
The GOC has reserved a block of rooms at the Sheraton Centre Toronto Hotel at a special conference rate of $199 per night (single occupancy) plus applicable taxes and other charges. To benefit from this rate, you will need to make your reservation by April 9, 2019, and identify yourself as being with the Society of Gynecologic Oncology of Canada – 2019.
A deposit equal to one night’s stay is required to hold your reservation. A refund of this deposit will be given to cancellations received until 72 hours prior to arrival. For cancellations received within 72 hours of arrival, the deposit is non-refundable.
On-line reservation: click here to make your reservation on-line
Toll-free Sheraton reservations: 1-888-627-7175
Direct to hotel: 1-416-361-1000
Sheraton Toronto Centre123 Queen Street, W.
Toronto, ON M5H 2M9
Rate informationRooms start at $199.00 per night
Save 10% with Air Canada on Flex, Latitude and Business Flexible classes when booking online. The discounted fares are available now for travel from from April 25, 2019 to May 7, 2019.
Click here to book your flight online and enter the promotion code Z4NCNVU1.
Porter Airlines is proud to offer a 10% discount on all available base fares (with the exception of the lowest class fare during a public seat sale) for travel to and from GOC’s 19th Annual CPD Meeting. The discounted fares are available now for travel from May 1, 2019 to May 6, 2019.
Click here to book your flight online and enter the promotion code GOC19 or through your travel agent using promo code GOC19.
Save with Westjet! 5% on Econo fares and 10% on EconoFlex and Premium fares. The discounted fares are available now for travel from April 25, 2019 to May 11, 2019.
Click here to book online and use coupon code W11WH2N and *group code WDD79.
*group code for travel agent use only.
GOC’s 2-day conference program features national and international speakers and educational courses. We offer several sponsorship packages, starting at the Bronze level ($5,000).
If you wish to discuss sponsorship opportunities, please contact email@example.com.
We would like to acknowledge the following companies for their support of our 19th Annual Continuing Professional Development Meeting in the form of sponsorship or educational grants:
DIAMOND PLUS: AstraZeneca
GOLD: Hoffmann-La Roche, Merck Canada
SILVER: Minogue Medical Inc.
BRONZE: Allen-Carey Scholarship Fund in Women’s Health, CAREpath, HOLOGIC Canada, Tesaro
OTHER SPONSORS: The Royal College of Physicians and Surgeons of Canada